Imipramine: A model drug for P450 research

被引：7

作者：

Brosen, K

Skjelbo, E

Nielsen, KK

机构：

来源：

CYTOCHROME P450, PT B | 1996年 / 272卷

关键词：

D O I：

10.1016/S0076-6879(96)72022-0

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：177 / 186

页数：10

共 18 条

[1] IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].

BROSEN, K ;

OTTON, SV ;

GRAM, LF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549

[2] STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].

BROSEN, K ;

KLYSNER, R ;

GRAM, LF ;

OTTON, SV ;

BECH, P ;

BERTILSSON, L .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684

[3] INHIBITION BY PAROXETINE OF DESIPRAMINE METABOLISM IN EXTENSIVE BUT NOT IN POOR METABOLIZERS OF SPARTEINE [J].

BROSEN, K ;

HANSEN, JG ;

NIELSEN, KK ;

SINDRUP, SH ;

GRAM, LF .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (04) :349-355

[4] ROLE OF P450IID6, THE TARGET OF THE SPARTEINE-DEBRISOQUIN OXIDATION POLYMORPHISM, IN THE METABOLISM OF IMIPRAMINE [J].

BROSEN, K ;

ZEUGIN, T ;

MEYER, UA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) :609-617

[5] FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].

BROSEN, K ;

SKJELBO, E ;

RASMUSSEN, BB ;

POULSEN, HE ;

LOFT, S .

BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214

[6]

GRAM LF, 1974, DAN MED BULL, V21, P218

[7] STEADY-STATE KINETICS OF IMIPRAMINE IN PATIENTS [J].

GRAM, LF ;

SONDERGAARD, I ;

CHRISTIANSEN, J ;

PETERSEN, GO ;

BECH, P ;

REISBY, N ;

IBSEN, I ;

ORTMANN, J ;

NAGY, A ;

DENCKER, SJ ;

JACOBSEN, O ;

KRAUTWALD, O .

PSYCHOPHARMACOLOGY, 1977, 54 (03) :255-261

[8]

GRAM LF, 1975, CLIN PHARMACOL THER, V17, P555

[9]

GRAM LF, 1983, CLIN PHARMACOL THER, V33, P353

[10]

LEMOINE A, 1993, MOL PHARMACOL, V43, P827

← 1 2 →